{
  "report_rows": [
    {
      "kpi": "Non-GAAP Operating EPS (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$1.95 vs. cons $1.82",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "P&C Combined Ratio (Q2'26)",
      "prediction": "MISS",
      "answer": "pred ~95.5% vs. cons ~94.0%",
      "confidence": "LOW"
    },
    {
      "kpi": "Consolidated Net Written Premium Growth (Q2'26 YoY)",
      "prediction": "MISS",
      "answer": "pred ~5.0% vs. cons ~6.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Combined Ratio Target Commentary",
      "prediction": "LOWER",
      "answer": "guide ~96% vs. cons ~95% (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Commercial Lines Renewal Pricing Trend",
      "prediction": "LOWER",
      "answer": "guide ~2% vs. cons ~3% (Q3 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Share Buyback Pace",
      "prediction": "BETTER",
      "answer": "guide ~1.0M shares vs. cons ~0.8M shares (Q3 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -1.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -2.3,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A likely cat-driven combined-ratio miss and further confirmation of commercial/personal/E&S pricing deceleration should push sell-side to trim FY2026 EPS and combined-ratio estimates even after an EPS beat, since the EPS beat is lower-quality (investment income/tax, not underwriting) while premium growth and margin trajectory both point to negative out-period revisions; with the stock having already re-rated to ~1.8x book on a hot run into the print, disappointment on growth/margin quality plus reiterated 92-98% target caution should extend the initial negative reaction over the following days rather than reverse it.",
  "day5_confidence": "LOW"
}